Protego Biopharma Heteroaryl Diamide IRE1/XBP1S Activator Patent EP4347568A1
Summary
The European Patent Office published patent application EP4347568A1 on 15 April 2026, filed by Protego Biopharma, Inc. and The Scripps Research Institute, covering heteroaryl diamide compounds as IRE1/XBP1S pathway activators. The application lists eight named inventors and spans multiple therapeutic classifications including metabolic, cardiovascular, musculoskeletal, and neurological disease indications. The patent is now publicly available and designates all EPC contracting states across the EU and beyond.
About this source
GovPing monitors EPO Patent Bulletin - Organic Chemistry (C07D) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 22 changes logged to date.
What changed
The European Patent Office published EP4347568A1, a patent application for heteroaryl diamide compounds classified as IRE1/XBP1S activators, filed by Protego Biopharma, Inc. and The Scripps Research Institute. The application claims priority across multiple IPC classifications spanning C07D (heterocyclic compounds), A61K (pharmaceutical preparations), and A61P (therapeutic activity classifications) covering metabolic, cardiovascular, musculoskeletal, and neurological indications. This publication makes the application available for public inspection and opposition proceedings.
For pharmaceutical and biotechnology companies developing compounds targeting the IRE1/XBP1S unfolded protein response pathway, this patent establishes prior art that could affect freedom-to-operate analyses. Companies pursuing similar heterocyclic amide structures for therapeutic applications should review the application's specific claims and designated state coverage to assess potential licensing or design-around obligations.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
HETEROARYL DIAMIDE IRE1/XBP1S ACTIVATORS
Publication EP4347568A1 Kind: A1 Apr 15, 2026
Applicants
Protego Biopharma, Inc., The Scripps Research Institute
Inventors
LABAUDINIERE, Richard F., TAIT, Bradley Dean, PETRASSI, Hank Michael James, KELLY, Jeffery W., WISEMAN, R. Luke, LEE, Kyunga, GUERRERO, Adrian Marco
IPC Classifications
C07D 231/40 20060101AFI20221202BHEP C07D 233/88 20060101ALI20221202BHEP C07D 401/12 20060101ALI20221202BHEP C07D 403/12 20060101ALI20221202BHEP A61K 31/415 20060101ALI20221202BHEP A61K 31/4164 20060101ALI20221202BHEP A61K 31/4439 20060101ALI20221202BHEP A61P 3/00 20060101ALI20221202BHEP A61P 9/00 20060101ALI20221202BHEP A61P 19/00 20060101ALI20221202BHEP A61P 25/00 20060101ALI20221202BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.